Teva's IGALMI Gains FDA Nod for First At-Home Agitation Treatment
Event summary
- Teva's IGALMI (dexmedetomidine) sublingual film approved by FDA for at-home use in treating agitation linked to schizophrenia, schizoaffective disorder, or bipolar I/II disorder.
- Approval based on Phase 3 SERENITY trial data showing safety and tolerability in 1,160 agitation episodes across 102 patients.
- Teva acquired IGALMI in October 2026 and submitted sNDA for at-home use in January 2026.
- IGALMI is the first FDA-approved treatment for self-administration at home during agitation episodes.
The big picture
Teva's FDA approval for IGALMI marks a strategic shift in treating agitation, moving care from healthcare settings to at-home environments. This aligns with broader industry trends toward patient-centered innovation and decentralized care models. The approval could enhance Teva's position in the neuroscience space, particularly if it successfully commercializes IGALMI as part of its growth strategy.
What we're watching
- Commercialization Strategy
- How Teva will position IGALMI in the competitive neuroscience market and the pace of market adoption.
- Reimbursement Dynamics
- Whether payers will cover IGALMI for at-home use, given its novel setting.
- Pipeline Expansion
- How this approval aligns with Teva's Pivot to Growth strategy and its ability to sustain innovation in neuroscience.
Related topics
